Synergistic Efficacy: Combination therapy using GLP1-E2 and low-dose anti-CD3 (aCD3) reduced diabetes incidence in late-stage prediabetic NOD mice to 38%, compared to 77% in controls.
Dual-Action Mechanism: While aCD3 restores beta-cell identity, the GLP1-E2 conjugate specifically targets beta cells to reduce endoplasmic reticulum (ER) stress and immunogenicity.
Enhanced Safety Profile: The use of low-dose aCD3 combined with GLP1-E2 provides potent protection without the systemic side effects typically associated with high-dose immunotherapy.
Sustained Remission: Disease protection persists even after treatment cessation, suggesting a fundamental shift in the intra-islet microenvironment.
Background: The Challenge of Type 1 Diabetes Progression
